Tumor-Derived Exosomes and Their Role in Cancer Progression

Advances in Clinical Chemistry

Volumn 74, Issue , 2016, Pages 103-141

  Whiteside, Theresa L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer progression; Exosome content; Exosomes; Exosomes in immunoregulation; Information transfer; Tumor microenvironment; Tumor derived exosomes

Indexed keywords

TUMOR MARKER; TUMOR PROTEIN;

CELL TRANSFORMATION; CHEMISTRY; DISEASE COURSE; EXOSOME; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOTHERAPY; METABOLISM; METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR REPROGRAMMING; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; THROMBOSIS; TUMOR MICROENVIRONMENT;

BIOMARKERS, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CELLULAR REPROGRAMMING; DISEASE PROGRESSION; EXOSOMES; GENE EXPRESSION; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; THROMBOSIS; TUMOR MICROENVIRONMENT;

EID: 84962766873     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2015.12.005     Document Type: Chapter

References (145)

1. Keller S., Ridinger J., Rupp A.K., Janssen J.W., Altevogt P. Body fluid derived exosomes as a novel template for clinical diagnostics. J. Transl. Med. 2011, 9:86.
2. Brinton L.T., Sloane H.S., Kester M., Kelly K.A. Formation and role of exosomes in cancer. Cell. Mol. Life Sci. 2015, 72:659-671.
3. Gould S.J., Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. J. Extracell. Vesicles 2013, 2:20389.
4. van der Pol E., Boing A.N., Harrison P., Sturk A., Nieuwland R. Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol. Rev. 2012, 64:676-705.
5. Wilson D.H., Rissin D.M., Kan C.W., Fournier D.R., Piech T., Campbell T.G., et al. The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J. Lab. Autom. 2015.
6. Harding C., Heuser J., Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 1983, 97:329-339.
7. Pan B.T., Johnstone R.M. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983, 33:967-978.
8. Boyiadzis M., Whiteside T.L. Information transfer by exosomes: a new frontier in hematologic malignancies. Blood Rev. 2015, 29:281-290.
9. Atay S., Godwin A.K. Tumor-derived exosomes: a message delivery system for tumor progression. Commun. Integr. Biol. 2014, 7:e28231.
10. Rak J., Guha A. Extracellular vesicles-vehicles that spread cancer genes. Bioessays 2012, 34:489-497.
11. Martins V.R., Dias M.S., Hainaut P. Tumor-cell-derived microvesicles as carriers of molecular information in cancer. Curr. Opin. Oncol. 2013, 25:66-75.
12. Raposo G., Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell Biol. 2013, 200:373-383.
13. Berleman J., Auer M. The role of bacterial outer membrane vesicles for intra- and interspecies delivery. Environ. Microbiol. 2013, 15:347-354.
14. Cocucci E., Meldolesi J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol. 2015, 25:364-372.
15. Colombo M., Moita C., van Niel G., Kowal J., Vigneron J., Benaroch P., et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J. Cell Sci. 2013, 126:5553-5565.
16. Kowal J., Tkach M., Thery C. Biogenesis and secretion of exosomes. Curr. Opin. Cell Biol. 2014, 29:116-125.
17. Marks M.S., Heijnen H.F., Raposo G. Lysosome-related organelles: unusual compartments become mainstream. Curr. Opin. Cell Biol. 2013, 25:495-505.
18. Wubbolts R., Leckie R.S., Veenhuizen P.T., Schwartzmann G., Mobius W., Hoernschemeyer J., et al. Proteomic and biochemical analysis of human B cell-derived exosomes. Potential implication for their function and multivesicular body formation. J. Biochem. 2003, 278:10963-10972.
19. Record M., Subra C., Silvente-Poirot S., Poirot M. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem. Pharmacol. 2011, 81:1171-1182.
20. Subra C., Grand D., Laulagnier K., Stella A., Lambeau G., Paillasse M., et al. Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. J. Lipid Res. 2010, 51:2105-2120.
21. Andreu Z., Yanez-Mo M. Tetraspanins in extracellular vesicle formation and function. Front. Immunol. 2014, 5:442.
22. Rana S., Zoller M. Exosome target cell selection and the importance of exosomal tetraspanins: a hypothesis. Biochem. Soc. Trans. 2011, 39:559-562.
23. Cocucci E., Racchetti G., Maldolesi J. Shedding microvesicles: artefacts no more. Trends Cell. Biol. 2009, 19:43-57.
24. Szczepanski M.J., Szajnik M., Welsh A., Whiteside T.L., Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica 2011, 96:1302-1309.
25. Karaziha P., Ceder S., Li Q., Panaretkis T. Tumor-derived exosomes: a message in the bottle. Biochem. Biophys. Acta 2012, 1826:103-111.
26. Park J.E., Tan H.S., Datta A., Lai R.C., Zhang H., Meng W., et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol. Cell. Proteomics 2010, 9:1085-1099.
27. King H.W., Michael M.Z., Gleadle J.M. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012, 12:421.
28. Yu X., Harris S.L., Levine A.J. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006, 66:4795-4801.
29. Atai N.A., Balaj L., van Veen H., Breakefield X.O., Jarzyna P.A., Van Noorden C.J., et al. Heparin blocks transfer of extracellular vesicles between donor and recipient cells. J. Neurooncol. 2013, 115:343-351.
30. Ostrowski M., Carmo N.B., Krumeich S., Fanget I., Raposo G., Savina A., et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol. 2010, 12:19-30. Suppl. pp. 1-13.
31. Bobrie A., Thery C. Unraveling the physiological functions of exosome secretion by tumors. Oncoimmunology 2013, 2:e22565.
32. Peinado H., Aleckovic M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
33. Kim J.W., Wieckowski E., Taylor D.D., Reichert T.E., Watkins S., Whiteside T.L. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 2005, 11:1010-1020.
34. Wieckowski E., Whiteside T.L. Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. Immunol. Res. 2006, 36:247-254.
35. Whiteside T.L. Immune responses to malignancies. J. Allergy Clin. Immunol. 2010, 125:S272-S283.
36. Wieckowski E.U., Visus C., Szajnik M., Szczepanski M.J., Storkus W.J., Whiteside T.L. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J. Immunol. 2009, 183:3720-3730.
37. Schuler P.J., Saze Z., Hong C.S., Muller L., Gillespie D.G., Cheng D., et al. Human CD4(+) CD39(+) regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73(+) exosomes or CD73(+) cells. Clin. Exp. Immunol. 2014, 177:531-543.
38. Bobrie A., Thery C. Exosomes and communication between tumours and the immune system: are all exosomes equal?. Biochem. Soc. Trans. 2013, 41:263-267.
39. Whiteside T.L. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem. Soc. Trans. 2013, 41:245-251.
40. Gabrielsson S., Scheynius A. Exosomes in immunity and cancer-friends or foes?. Semin. Cancer Biol. 2014, 28:1-2.
41. Robbins P.D., Morelli A.E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 2014, 14:195-208.
42. Mulcahy L.A., Pink R.C., Carter D.R. Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles 2014, 3:2464.
43. Singh R., Pochampally R., Watabe K., Lu Z., Mo Y.Y. Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Mol. Cancer 2014, 13:256.
44. Fong M.Y., Zhou W., Liu L., Alontaga A.Y., Chandra M., Ashby J., et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 2015, 17:183-194.
45. Umezu T., Ohyashiki K., Kuroda M., Ohyashiki J.H. Leukemia cell to endothelial cell communication via exosomal miRNAs. Oncogene 2013, 32:2747-2755.
46. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010, 120:457-471.
47. Demory Beckler M., Higginbotham J.N., Franklin J.L., Ham A.J., Halvey P.J., Imasuen I.E., et al. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol. Cell. Proteomics 2013, 12:343-355.
48. Garnier D., Magnus N., Lee T.H., Bentley V., Meehan B., Milsom C., et al. Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. J. Biol. Chem. 2012, 287:43565-43572.
49. Khan S., Jutzy J.M., Aspe J.R., McGregor D.W., Neidigh J.W., Wall N.R. Survivin is released from cancer cells via exosomes. Apoptosis 2011, 16:1-12.
50. Khan S., Aspe J.R., Asumen M.G., Almaguel F., Odumosu O., Acevedo-Martinez S., et al. Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br. J. Cancer 2009, 100:1073-1086.
51. Schuler P.J., Schilling B., Harasymczuk M., Hoffmann T.K., Johnson J., Lang S., et al. Phenotypic and functional characteristics of CD4+ CD39+ FOXP3+ and CD4+ CD39+ FOXP3neg T-cell subsets in cancer patients. Eur. J. Immunol. 2012, 42:1876-1885.
52. Atay S., Banskota S., Crow J., Sethi G., Rink L., Godwin A.K. Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:711-716.
53. Al-Nedawi K., Meehan B., Micallef J., Lhotak V., May L., Guha A., et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 2008, 10:619-624.
54. Kogure T., Lin W.L., Yan I.K., Braconi C., Patel T. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology 2011, 54:1237-1248.
55. Roccaro A.M., Sacco A., Maiso P., Azab A.K., Tai Y.T., Reagan M., et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest. 2013, 123:1542-1555.
56. Umezu T., Tadokoro H., Azuma K., Yoshizawa S., Ohyashiki K., Ohyashiki J.H. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood 2014, 124:3748-3757.
57. Webber J., Steadman R., Mason M.D., Tabi Z., Clayton A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 2010, 70:9621-9630.
58. Aga M., Bentz G.L., Raffa S., Torrisi M.R., Kondo S., Wakisaka N., et al. Exosomal HIF1alpha supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene 2014, 33:4613-4622.
59. Taylor D.D., Gercel-Taylor C., Lyons K.S., Stanson J., Whiteside T.L. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin. Cancer Res. 2003, 9:5113-5119.
60. Costa-Silva B., Aiello N.M., Ocean A.J., Singh S., Zhang H., Thakur B.K., et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 2015, 17:816-826.
61. Lazaro-Ibanez E., Sanz-Garcia A., Visakorpi T., Escobedo-Lucea C., Siljander P., Ayuso-Sacido A., et al. Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes. Prostate 2014, 74:1379-1390.
62. Muller-Haegele S., Muller L., Whiteside T.L. Immunoregulatory activity of adenosine and its role in human cancer progression. Expert. Rev. Clin. Immunol. 2014, 10:897-914.
63. Gross J.C., Chaudhary V., Bartscherer K., Boutros M. Active Wnt proteins are secreted on exosomes. Nat. Cell Biol. 2012, 14:1036-1045.
64. Huber H.J., Holvoet P. Exosomes: emerging roles in communication between blood cells and vascular tissues during atherosclerosis. J. Curr. Opin. Lipidol. 2015, 26:412-419.
65. Lima L.G., Leal L.C., Vargas G., Porto-Carreiro I., Monteiro R.Q. Intercellular transfer of tissue factor via up-take of tumor-derived microvesicles. Thromb. Res. 2013, 132:450-456.
66. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9:654-659.
67. Thery C., Amigorena S., Raposo G., Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. 2006, Chapter 3:Unit 3.22.
68. Taylor D.D., Chou I.N., Black P.H. Isolation of plasma membrane fragments from cultured murine melanoma cells. Biochem. Biophys. Res. Commun. 1983, 113:470-476.
69. Muller L., Hong C.S., Stolz D.B., Watkins S.C., Whiteside T.L. Isolation of biologically-active exosomes from human plasma. J. Immunol. Methods 2014, 411:55-65.
70. Iero M., Valenti R., Huber V., Filipazzi P., Parmiani G., Fais S., et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008, 15:80-88.
71. Taylor D.D., Shah S. Methods of isolating extracellular vesicles impact down-stream analyses of their cargoes. Methods 2015, 87:3010.
72. Hong C.S., Muller L., Boyiadzis M., Whiteside T.L. Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia. PLoS One 2014, 9:e103310.
73. Saleem N., Abdel-Mageed A.B. Tumor-derived exosomes in oncogenic reprogramming and cancer progression. Cell. Mol. Life Sci. 2015, 72:1-10.
74. Shiga K., Hara M., Nagasaki T., Takahashi H., Takeyama H. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers 2015, 7:2443-2458.
75. Webber J., Yeung V., Clayton A. Extracellular vesicles as modulators of the cancer microenvironment. Semin. Cell Dev. Biol. 2015, 40:27-34.
76. Webber J., Steadman R., Mason M.D., Tabi Z., Clayton A. Cancer exosomes trigger fibroblast to myyofibroblast differentiation. Cancer Res. 2010, 70:9621-9630.
77. Borges F.T., Melo S.A., Ozdemir B.C., Kato N., Revuelta I., et al. TGF-beta1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J. Am. Soc. Nephrol. 2013, 24:385-392.
78. Corey D.M., Rinkevich Y., Weissman I.L. Dynamic patterns of clonal evolution in tumor vasculature underlie alterations in lymphocyte-endothelial recognition to foster tumor immune escape. Cancer Res. 2015, Epub ahead of print.
79. Grange C., Tapparo M., Collino F., Vitillo L., Damasco C., et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011, 71:5346-5356.
80. Park J.E., Tan H.S., Datta A., Lai R.C., Zhang H., Meng W., et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol. Cell Proteomics 2010, 9:1085-1099.
81. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10:1470-1476.
82. Al-Nedawi K., Meehan B., Kerbel R.S., Allison A.C., Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3794-3799.
83. Nazarenko I., Rana S., Baumann A., McAlear J., Hellwig A., Trendelenburg M., et al. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 2010, 70:1668-1678.
84. Zhou W., Fong M.Y., Min Y., Somlo G., Liu L., Palomares M.R., et al. Cancer secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 2014, 25:501-515.
85. Sheldon H., Heikamp E., Turlet H., Dragovic R., Thomas P., Oon C.E., Leek R., et al. New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood 2010, 116:2385-2394.
86. Galon J., Mlecnik B., Bindea G., Angell H.K., Berger A., Lagorce C., Lugli A., et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumors. J. Pathol. 2014, 232:199-209.
87. Fridman W.H., Galon J., Pages F., Tartour E., Sautes-Fridman C., Kroemer G. Prognosrtic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res. 2011, 71:5601-5605.
88. Czystowska M., Han J., Szczepanski M.J., Szajnik M., Quadrini K., Brandwein H., et al. IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ. 2009, 16:708-718.
89. Bergmann C., Strauss L., Wieckowski E., Czystowska M., Albers A., Wang Y., et al. Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck 2009, 31:371-380.
90. Hoffmann T.K., Dworacki G., Tsukihiro T., Meidenbauer N., Gooding W., Johnson J.T., et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin. Cancer Res. 2002, 8:2553-2562.
91. Lundholm M., Schroder M., Nagaeva O., Baranov V., Widmark A., Mincheva-Nilsson L., et al. Prostate-tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One 2014, 9:e108924.
92. Clayton A., Mitchell J.P., Court J., Linnane S., Mason M.D., Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J. Immunol. 2008, 180:7249-7258.
93. Xiang X., Poliakov A., Liu C., Liu Y., Deng Z.B., Wang J., et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer 2009, 124:2621-2633.
94. Altevogt P., Bretz N.P., Ridinger J., Utikal J., Umansky V. Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. Semin. Cancer Biol. 2014, 28:51-57.
95. Filipazzi P., Burdek M., Villa A., Rivoltini L., Huber V. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin. Cancer Biol. 2012, 22:342-349.
96. Szajnik M., Czystowska M., Szczepanski M.J., Mandapathil M., Whiteside T.L. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One 2010, 5:e11469.
97. Mrizak D., Martin N., Barjon C., Jimenez-Pailhes A.S., Mustapha R., Niki T., et al. Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. J. Natl. Cancer Inst. 2015, 107:363.
98. Greening D.W., Gopal S.K., Xu R., Simpson R.J., Chen W. Exosomes and their roles in immune regulation and cancer. Semin. Cell Dev. Biol. 2015, 40:72-81.
99. Liu C., Yu S., Zinn K., Wang J., Zhang L., Jia Y., et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 2006, 176:1375-1385.
100. Pucci F., Pittet M.J. Molecular pathways: tumor-derived microvesicles and their interactions with immune cells in vivo. Clin. Cancer Res. 2013, 19:2598-2604.
101. Bretz N.P., Ridinger J., Rupp A.K., Rimbach K., Keller S., Rupp C., et al. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J. Biol. Chem. 2013, 288:36691-36702.
102. Yang C., Kim S.H., Bianco N.R., Robbins P.D. Tumor-derived exosomes confer antigen-specific immunosuppression in a murine delayed-type hypersensitivity model. PLoS One 2011, 6:e22517.
103. Zhang H.G., Grizzle W.E. Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am. J. Pathol. 2014, 184:28-41.
104. Atay S., Banskota S., Crow J., Sethi G., Rink L., Godwin A.K. Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc. Natl. Acad. Sci. USA 2014, 111:711-716.
105. Hood J.L., San R.S., Wickline S.A. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011, 71:3792-3801.
106. Yu S., Liu C., Su K., Wang J., Liu Y., Zhang L., et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 2007, 178:6867-6875.
107. Safaei R., Larson B.J., Cheng T.C., Gibson M.A., Otani S., Naerdemann W., et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol. Cancer Ther. 2005, 4:1595-1604.
108. Corcoran C., Rani S., O'Brien K., O'Neill A., Prencipe M., Sheikh R., et al. Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes. PLoS One 2012, 7:e50999.
109. Mao L., Li J., Chen W.X., Cai Y.Q., Yu D.D., Zhong S.L., et al. Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs. Tumor Biol. 2015, [Epub ahead of print].
110. Challagundla K.B., Wise P.M., Neviani P., Murtadha M., Xu T., Knnedy R., et al. Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chermotherapy. J. Natl. Cancer Inst. 2015, 107.
111. Ciravolo V., Huber V., Ghedini G.C., Venturelli E., Bianchi F., Campiglio M., et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J. Cell. Physiol. 2012, 227:658-667.
112. Amorim M., Fernandes G., Oliveira P., Martins-de-Souza D., Dias-Netoand E., Nunes D. The overexpression of a single oncogene (ERBB2/HER2) alters the proteomic landscape of extracellular vesicles. Proteomics 2014, 14:1472-1479.
113. Federici C., Petrucci F., Caimi S., Cesolini A., Logozzi M., Borghi M., et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One 2014, 9:e88193.
114. Czystowska M., Szczepanski M.J., Szajnik M., Quadrini K., Brandwein H., Hadden J.W., et al. Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic. Cancer Immunol. Immunother. 2011, 60:495-506.
115. Putz U., Howitt J., Doan A., Goh C.P., Low L.H., Silke J., et al. The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells. Sci. Signal. 2012, 5. ra70.
116. Kim J.W., Tsukishiro T., Johnson J.T., Whiteside T.L. Expression of pro- and antiapoptotic proteins in circulating CD8+ T cells of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2004, 10:5101-5110.
117. Hartman Z.C., Wei J., Glass O.K., Guo H., Lei G., Yang X.Y., et al. Increasing vaccine potency through exosome antigen targeting. Vaccine 2011, 29:9361-9367.
118. Gu X., Erb U., Buchler M.W., Zoller M. Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice. Int. J. Cancer 2015, 136:E74-E84.
119. Nilsson J., Skog J., Nordstrand A., Baranov V., Mincheva-Nilsson L., Breakefield X.O., et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br. J. Cancer 2009, 100:1603-1607.
120. Rolfo C., Castiglia M., Hong D., Alessandro R., Mertens I., Baggerman G., et al. Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim. Biophys. Acta 1846, 2014:539-546.
121. Santiago-Dieppa D.R., Steinberg J., Gonda D., Cheung V.J., Carter B.S., Chen C.C. Extracellular vesicles as a platform for "liquid biopsy" in glioblastoma patients. Expert. Rev. Mol. Diagn. 2014, 14:819-825.
122. Szajnik M., Derbis M., Lach M., Patalas P., Michalak M., Drzewiecka H., et al. Exosomes in plasma of patients with ovarian carcinoma: potential biomarkers of tumor progression and response to therapy. Gynecol. Obstet. (Sunnyvale) 2013, (Suppl. 4):3.
123. Hong C.S., Muller L., Whiteside T.L., Boyiadzis M. Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia. Front. Immunol. 2014, 5:160.
124. Kalra H., Simpson R.J., Ji H., Aikawa E., Altevogt P., Askenase P., et al. Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol. 2012, 10:e1001450.
125. Hong B.S., Cho J.H., Kim H., Choi E.J., Rho S., Kim J., et al. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics 2009, 10:556.
126. J. Baran, M. Baj-Krzyworzeka, K. Weglarczyk, R. Szatanek, M. Zembala, J. Barbasz, et al., Circulating tumor-derived microvesicles in plasma of gastric cancer patients, Cancer Immunol. Immunother. 59, 841-850.
127. Muller L., Muller-Haegele S., Mitsuhashi M., Gooding W., Okada H., Whiteside T.L. Exosomes isolated from plasma of glioma patients enrolled in a vaccination trial reflect antitumor immune activity and might predict survival. Oncoimmunology 2015, 4:e1008347.
128. Esquela-Kerscher A., Slack F.J. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 2006, 6:259-269.
129. Henderson M.C., Azorsa D.O. The genomic and proteomic content of cancer cell-derived exosomes. Front. Oncol. 2012, 2:38.
130. Nolte-'t Hoen E.N., Buermans H.P., Waasdorp M., Stoorvogel W., Wauben M.H., 't Hoen P.A. Deep sequencing of RNA from immune cell-derived vesicles uncovers the selective incorporation of small non-coding RNA biotypes with potential regulatory functions. Nucleic Acids Res. 2012, 40:9272-9285.
131. Roberson C.D., Atay S., Gercel-Taylor C., Taylor D.D. Tumor-derived exosomes as mediators of disease and potential diagnostic biomarkers. Cancer Biomark. 2010, 8:281-291.
132. Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110:13-21.
133. Ogata-Kawata H., Izumiya M., Kurioka D., Honma Y., Yamada Y., Furuta K., et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One 2014, 9:e92921.
134. Roth P., Wischhusen J., Happold C., Chandran P.A., Hofer S., Eisele G., et al. A specific miRNA signature in the peripheral blood of glioblastoma patients. J. Neurochem. 2011, 118:449-457.
135. Cazzoli R., Buttitta F., Di Nicola M., Malatesta S., Marchetti A., Rom W.N., et al. microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J. Thorac. Oncol. 2013, 8:1156-1162.
136. Corcoran C., Friel A.M., Duffy M.J., Crown J., O'Driscoll L. Intracellular and extracellular microRNAs in breast cancer. Clin. Chem. 2011, 57:18-32.
137. Whiteside T.L. The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert. Rev. Mol. Diagn. 2015, 15(10):1293-1310.
138. Silva J., Garcia V., Zaballos A., Provencio M., Lombardia L., Almonacid L., et al. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur. Respir. J. 2011, 37:617-623.
139. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
140. El Andaloussi S., Mager I., Breakefield X.O., Wood M.J.A. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat. Rev. 2013, 12:347-357.
141. Gyorgy B., Hung M.E., Breakefield X.O., Leonard J.N. Therapeutic applications of extracellular vesicles: clinical promise and open questions. Annu. Rev. Pharmacol. Toxicol. 2015, 55:439-464.
142. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9:581-593.
143. Raposo G., Nijman H.W., Stoorvogel W., Liejendekker R., Harding C.V., Melief C.J., et al. B lymphocyte secrete antigen-presenting vesicles. J. Exp. Med. 1996, 183:1161-1172.
144. T. Aung, B. Chapuy, D. Vogel, D. Wenzel, M. Oppermann, M. Lahmann, et al., Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma mpdulated by ATP-binding cassette transporter A3, Proc. Natl. Acad. Sci. USA 108, 15336-15341.
145. Marleau A.M., Chen C.S., Joyce J.A., Tullis R.H. Exosome removal as a therapeutic adjuvant in cancer. J. Transl. Med. 2012, 10:10.